Third Quarter ACV of $45 Million, Representing 17% Growth
Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance
Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended
Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference. The live presentation will take place on Tuesday, November 10, 2026 at 9:30
Schrödinger, Inc. (NASDAQ:SDGR) today reported that on October 21, 2026, the company granted restricted stock units (RSUs) with respect to 5,716 shares of the company’s common stock to five newly hired employees. These
Schrödinger, Inc. (NASDAQ:SDGR) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
New study uncovers multi-lithium ion clustering in common battery electrolytes, paving the way for improved battery performance and design
Schrödinger, Inc. (NASDAQ:SDGR) today announced the publication of new
Schrödinger, Inc. (NASDAQ:SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company’s common stock to three newly hired employees.
AUSTIN, Texas, Sept. 14, 2026 /CNW/ -- USA News Group News Commentary - Artificial intelligence is moving from the edges of drug discovery toward its center, and the market built around it is expanding quickly. Grand
Tectora secures $55 million Series A investment from NEA and RA Capital Management
Schrödinger, Inc. (NASDAQ:SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New
AUSTIN, Texas, Sept. 3, 2026 /CNW/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug
Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday,
Schrödinger, Inc. (NASDAQ:SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These
AUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and
Second Quarter ACV of $30 Million, Representing 27% Growth
Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery
Schrödinger, Inc. (NASDAQ:SDGR) today announced financial
Schrödinger, Inc. (NASDAQ:SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. Building on a
Collaboration with NVIDIA and Google Cloud Provide Additional Tools and Compute Access
Schrödinger, Inc. (NASDAQ:SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist
